The recent proposal for histological subtyping of pulmonary adenocarcinoma by predominant pattern and introduction of the terms adenocarcinoma in situ and minimally invasive adenocarcinoma to replace the term bronchioloalveolar carcinoma by the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society has led us to conduct a study of 104 patients with early-stage primary pulmonary adenocarcinoma (T1N0M0), with a view to histological subtype as defined by the new proposal and clinical outcome. None of the clinical parameters of our patient population (type of surgery, age, gender, tumor size, and comorbidities) showed any statistically significant correlation with outcome, except for associated malignancies, which not surprisingly appeared to have a negative impact on survival. In addition, statistical analyses of the histological characteristics to include tumor differentiation and the percentage of a lepidic or bronchioloalveolar component did not show any statistically significant values in terms of survival. Our results failed to show any statistically significant difference of survival between those T1N0M0 adenocarcinomas with a lepidic component and those without, thus questioning the use of terms such as in situ or minimally invasive adenocarcinoma. On the basis of our results, we consider that the outcome for patients with T1N0M0 disease is still best determined by appropriate staging rather than by changes in the pathology nomenclature of adenocarcinoma. The number of deaths due to lung cancer among this group was approximately 158 thousand. Also according to SEER, the age group more commonly affected is individuals between the ages of 55 and 74 years, with a median age at diagnosis of 71 years. Although lung cancer is also seen in younger age groups, people under 45 years of age represent approximately 2% of the total number of cases, while those people between the ages of 45 and 54 years represent approximately 9% of the total number of cases. It is also suggested that factors such as smoking, dietary habits, family history, and chemical exposure to compounds such as asbestos, radon, and silica among many others may play a role in lung cancer pathogenesis. Of all the different types of lung cancer, adenocarcinoma is currently the most frequent.
Compared with other types of malignancies, lung cancer is the leading cause of death in the United States. According to the Surveillance Epidemiology and End Results (SEER) (http://www.cdc.gov/cancer/lung/statistics/index.html and http://seer.cancer.gov/csr/1975_2008/) in the year 2007, more than 203 thousand people were diagnosed with lung carcinoma, representing approximately 110 thousand men and 93 thousand women. The number of deaths due to lung cancer among this group was approximately 158 thousand. Also according to SEER, the age group more commonly affected is individuals between the ages of 55 and 74 years, with a median age at diagnosis of 71 years. Although lung cancer is also seen in younger age groups, people under 45 years of age represent approximately 2% of the total number of cases, while those people between the ages of 45 and 54 years represent approximately 9% of the total number of cases. It is also suggested that factors such as smoking, dietary habits, family history, and chemical exposure to compounds such as asbestos, radon, and silica among many others may play a role in lung cancer pathogenesis. Of all the different types of lung cancer, adenocarcinoma is currently the most frequent.
In an effort to better define clinical behavior regarding small size adenocarcinomas, various studies have used different ways to address this issue.
A recent publication endorsed by the World Health Organization (WHO) 1 has declared small adenocarcinomas with a pure lepidic growth pattern and absence of stromal, pleural, or vascular invasion as bronchioloalveolar carcinoma. In addition, more recently, in a study conducting a review of the current literature, the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society 2 proposed that tumors up to 3.0 cm in greatest dimension with a pure lepidic growth pattern and lacking stromal, vascular, or pleural invasion should be categorized as in situ adenocarcinoma. Also, the same group designated a separate category of minimally invasive adenocarcinoma for tumors with a predominantly lepidic growth pattern and o5 mm invasion in greatest dimension in any one focus.
Following those parameters, we conducted a study of 104 patients diagnosed with early-stage adenocarcinoma (T1N0M0) of all histological types and found that when all these tumors are viewed as a group, there is no statistically significant correlation between histology and survival and that terms such as in situ adenocarcinoma or minimally invasive adenocarcinoma do not have any significant clinical impact. Thus, we still consider that staging is the most important parameter to predict prognosis. A detailed clinical, radiological, surgical, and pathological assessment of these tumors is herein presented.
Materials and methods

Materials
A search for tumors in the category of T1 adenocarcinoma of the lung was conducted from the files of the Departments of Pathology and Thoracic Surgery at MD Anderson Cancer Center (Houston, TX, USA) between the years 2005 and 2010. The following criteria were followed:
Only patients with a diagnosis of primary adenocarcinoma of the lung who underwent surgical resection at MD Anderson Cancer Center were included in this study. All patients had to be properly clinically staged at the time of surgery. All radiological imaging films available had to be reviewed by the radiologists. All tumors had to measure at least 0.5 cm, but no more than 3 cm in greatest diameter. All surgical resections had to undergo pathological re-evaluation to verify not only the size of the tumor but also the histological growth pattern of the tumor.
J All available hematoxylin-and eosin-stained sections were evaluated; in those cases in which only a lepidic growth pattern was identified, the entire tumor was submitted for evaluation. On the basis of those parameters, a group of 248 cases was identified, which met the specified size criteria (0.5-3.0 cm). However, only 104 patients were finally selected in whom there was no evidence of lymph node and pleural involvement or metastatic disease (T1N0M0). In addition, patients with a prior history of lung carcinoma were excluded.
Methods
Clinical features. Demographic data were collected from our institutional computerized system about age, gender, presenting symptoms, comorbidities, associated malignancies, and type of surgical resection.
Radiology. Three chest radiologists (EMM, MFB, and MCG), who were blinded to the clinical outcome and the histopathological diagnosis of all cases, reviewed the preoperative chest CT scans and differences were resolved by consensus. Nodules were designated as: ground glass, defined as a hazy increased attenuation in the lung that does not obliterate the bronchial and vascular margins; solid, defined as homogeneous soft tissue attenuation; and part solid, defined as a nodule that consists of both ground glass and solid soft tissue attenuation components.
Pathology. Re-examination of all pathological material was conducted by three chest pathologists (AW, NK, and CAM). Histological re-evaluation of Early-stage pulmonary adenocarcinoma the available preoperative biopsies (n ¼ 66) as well as the resection material (n ¼ 104) was performed. The percentage of a lepidic component was recorded for each of the biopsy specimens. The resected tumors were separated into the conventional categories of well, moderately and poorly differentiated adenocarcinoma based on tumor architecture, nuclear atypia, and mitotic activity. In addition, the tumors were further subdivided into categories based on the percentage of a lepidic growth pattern.
Statistical analysis. Association between clinical outcome and the following parameters was assessed: age, gender, comorbidities, associated malignancies, type of surgical treatment, tumor size, and tumor histology. Univariable and multivariable Cox proportional hazard regression statistical analyses were conducted using SSPS, version 17.0. All those covariates that had a P-value o0.25 in the univariable analysis were then entered into the multivariable analysis. Stepwise backward elimination using Wald's statistic was performed to obtain the final multivariable regression model. The log-rank test was performed when creating survival curves using the Kaplan-Meier method. Statistical significance was defined as a P-value r0.05.
Results
Clinical Features
Among the patients used in this study, 65 were women and 39 were men between the ages of 49 and 86 years (mean 65 years). In all, 41 patients had one other associated malignancy and 7 patients had two or more associated malignancies, which included invasive melanoma (n ¼ 9), lymphoma/leukemia (n ¼ 4), prostatic carcinoma (n ¼ 8), breast carcinoma (n ¼ 10), renal cell carcinoma (n ¼ 5), endometrial carcinoma (n ¼ 1), esophageal carcinoma (n ¼ 2), soft tissue sarcoma (n ¼ 2), colonic carcinoma (n ¼ 2), gastric carcinoma (n ¼ 1), head and neck squamous cell carcinoma (n ¼ 3), Merkel cell carcinoma (n ¼ 2), urothelial cell carcinoma of the bladder (n ¼ 1), malignant salivary gland tumor (n ¼ 1), chordoma (n ¼ 1), and papillary thyroid carcinoma (n ¼ 4). In these patients, the finding of a pulmonary mass was detected during follow-up for their respective prior malignancy. In 56 patients, cough, dyspnea, and chest pain led to radiographic evaluation.
In addition, each one of the patients was also evaluated for comorbidities, which included cerebrovascular disease (n ¼ 8), diabetes mellitus (n ¼ 3), chronic alcohol use (n ¼ 6), arrhythmias (n ¼ 5), chronic obstructive pulmonary disease (n ¼ 11), cardiovascular disease (n ¼ 5), hypertension (n ¼ 51), as well as smoking history (n ¼ 79).
All patients underwent surgical resection of their tumors with respective proper surgical staging. In 91 patients, lobectomy was the treatment of choice, while in 13 patients a wedge resection or segmentectomy was performed. In all the cases, lymph nodes were dissected for appropriate staging. Statistical analysis of the types of procedure performed in these 104 patients demonstrated a lack of statistical significance (P ¼ 0.599) as to whether the patients were treated with lobectomy or wedge resection/segmentectomy ( Table 1) .
None of the clinical parameters studied with respect to outcome showed statistical significance, except for associated malignancies, which appeared to impact negatively on survival (P ¼ 0.049) ( Table 1) .
Radiological Features
Preoperative chest CT scans were available for review in 101 of the 104 study patients. In 49 patients, the tumors were described as solid, 47 as partly solid, and 6 as pure ground-glass opacities.
Pathological Features
Retrospective analysis of the preoperative lung biopsy was possible in 66 cases, 24 of which showed a pure lepidic growth pattern. The biopsy specimens were also correlated with the surgical resection material of the tumors showing 19 cases with pure lepidic growth pattern, while in 5 cases the resected specimens showed combined lepidic and nonlepidic growth patterns (including acinar, papillary, and solid patterns). Grossly, the resected tumors were described as well-demarcated intrapulmonary masses of light tan to brown color and soft to firm consistency, ranging in size from 0.5 to 3.0 cm in greatest diameter. On the basis of these set criteria, 13 tumors were between 0.5 and 1.0 cm; 55 tumors between 1.1 and 2.0 cm; and 36 tumors between 2.1 and 3.0 cm.
The 104 tumors were initially analyzed using the conventional approach and using the architectural pattern of the glandular proliferation, nuclear atypia, and mitotic activity. On the basis of those parameters, the tumors were graded as: Following this stratification of histological types, we encountered no statistical significance between tumor differentiation and outcome with a univariable P-value of 0.105 (Table 1) . Further, multivariable analysis also showed no statistical significance with a P-value of 0.125 (Table 2 ).
In addition, the tumors were further analyzed and subdivided into two main categories: (1) those showing a lepidic or bronchioloalveolar growth pattern and (2) those with no histological evidence of a lepidic growth pattern. Histological evaluation of 104 cases disclosed that 59 cases showed evidence of a lepidic component, which was further divided into percentages:
In total, the number of cases showing 0 or r50% of a lepidic component corresponded to 66 cases, while those with more than 50% of a lepidic component represented 38 cases. Again, no statistical significance was encountered between tumors with r50% or 450% lepidic components and outcome with a univariable P-value of 0.121 (Table 1) . Further, multivariable analysis also showed no statistical significance with a P-value of 0.834 (Table 2) .
It is evident from Table 2 that even when the initial statistical cutoff P-value of o0.25 was lowered to 0.125, only tumor differentiation met the requirement for multivariable analysis as the percentage of a lepidic component did not converge into the final step, as this variable maintained a Early-stage pulmonary adenocarcinoma P-value of 0.834. Nevertheless, we still proceeded to analyze those tumors differently as presented below. Important to note is that none of the tumors herein presented fulfilled the criteria of 'minimally invasive adenocarcinoma' as per the new proposed classification. 2 In view of the univariable statistically significant association between lung carcinoma and associated malignancies in relation to outcome (P ¼ 0.049), the entire group of patients was further separated into two groups: (1) 48 patients in whom there was another associated malignancy and (2) 56 patients in whom there was not. The tumors of the latter group were then also subdivided into those with a lepidic component and those without. In this group, we identified 27 out of 56 cases with evidence of a lepidic component. The lepidic component was distributed as follows: (Table 3 ). In addition, the presence of a pure lepidic pattern yielded a P-value of 0.262 (Table 3) . Furthermore, we proceeded to perform Kaplan-Meier survival curves by comparing cases with no lepidic component against those with different proportions of a lepidic pattern. An initial trend towards better survival, although not statistically significant, was noted for cases with any lepidic component compared with those without (P ¼ 0.058) (Figure 4a ). However, when the tumors with lepidic component were separated by specific percentage, we did not encounter any statistical significance among the three groups (o25, 25-50, and 450%) (P ¼ 0.102) (Figure 4b ), nor when divided into two groups (r50 and 450%) (P ¼ 0.118) (Figure 4c ), or even for tumors with pure lepidic pattern (the so-called 'in situ adenocarcinoma') (P ¼ 0.134) (Figure 4d ).
Follow-Up
Clinical follow-up was obtained in all patients (100%) with a median follow-up time of 48 months (range 1-82 months). A total of 20 patients died (19%) and 84 patients (81%) are alive without recurrence. Further analysis of the group of 56 patients in whom there was no other associated malignancy showed that the median follow-up was 57 months (11-82 months). In this group of patients, 7 patients died (13%) and 49 (87%) are alive with no recurrence. In the patients who have died, we were not able to obtain further information regarding the exact cause of death. However, one of those patients had been followed for severe arrhythmias and hypertension. To the best of our knowledge none of these patients had recurrent disease. Comparison of these two patient groups showed a similar trend for cumulative survival (Figures 5 and 6 ). In addition, a comparative survival probability between patients with associated malignancies and those with no other malignancy is also presented (Table 4) .
Discussion
Over the past several years, advances in the treatment of lung cancer have made the histopathological separation of the different types of lung carcinoma important to choose optimal treatment modalities. 3 In view of these efforts, it becomes even more important to try to separate tumors that may show better clinical behavior from those that may follow a more aggressive clinical course. In addition, it is highly important to point out that tumor staging at the time of diagnosis plays an important role in the treatment and prognosis for patients. Thus, early diagnosis likely represents the most important parameter in terms of survival. In this setting, it is also important to mention that patients whose tumors are staged as T1N0M0 will be treated with complete surgical resection, either by lobectomy or wedge resection/segmentectomy, and close clinical followup. Patients with more advanced stages of the disease are likely to receive additional medical therapy. In recent years, the term bronchioloalveolar carcinoma has been under scrutiny, and different views on the subject have been presented. Historically, the term has been under much debate and different views have been presented to attest to its clinical behavior without, however, producing a unifying agreement. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] In 1960, Liebow 20 introduced the term bronchioloalveolar carcinoma to describe a well-differentiated adenocarcinoma that may have long dormancy or slow growth, particularly in those patients presenting with isolated nodules. More recently and exclusively looking at the solitary nodule pattern, there have been proposals for a change in the nomenclature of pulmonary adenocarcinomas with a pure lepidic or bronchioloalveolar growth pattern. The first one of these suggestions was made in the 2004 WHO publication on Tumors of the Lung, Pleura, Thymus, and Heart. 1 In this publication, a few series of cases were cited that, according to the authors, provided the necessary evidence for such a change in terminology. [21] [22] [23] [24] Interestingly, close review of those citations shows that in some cases the 'criteria' imposed by the WHO authors were not actually met in the evaluation of the tumors presented. The main theory has been that owing to the indolent behavior by tumors with pure lepidic Early-stage pulmonary adenocarcinoma growth, the 5-year survival is nearly 100%. 22 However, such a view has generated some controversy. 25, 26 By following the criteria imposed by the WHO, various authors have obtained different results. For instance, Breathnach et al 27 in a study focusing on the survival and recurrences of bronchioloalveolar carcinoma stage I disease found that when comparing bronchioloalveolar carcinoma stage I and adenocarcinoma of the conventional type, the 5-year survival rate for bronchioloalveolar carcinoma is 83 and 63% for other types of adenocarcinoma. In a different study, Ebright et al 28 concluded that the most important predictors of survival in bronchioloalveolar carcinoma are clinical and pathological stage rather than the degree of invasion on histological examination. More recently, another change in nomenclature has been presented. 2 This time the authors suggested changing the nomenclature to two different terms: (1) in situ adenocarcinoma to describe those tumors previously known as bronchioloalveolar carcinoma, and (2) minimally invasive adenocarcinoma to describe those tumors with a predominant lepidic growth pattern and an area of minimal invasion (r5 mm). This new proposal was based on a literature review rather than on an actual clinicopathological study. The authors stated that they had reviewed 11 thousand citations from which they selected 312 that 'met specified eligibility.' The citations supporting their notion, interestingly, have been presented as series of bronchioloalveolar carcinomas or small adenocarcinomas (o2 cm) [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] (Table 5 ). In some of these, the actual size of the tumor has been at best vague leaving the impression that some of these lesions may not even qualify as adenocarcinoma, but would rather have to be classified as atypical adenomatous hyperplasia (tumors with lepidic growth and size r0.5 cm). Nevertheless, the main idea concluded from these citations was that such a tumor behaves in an indolent manner, a feature that, according to the authors of that publication, qualifies these lesions to be renamed in situ adenocarcinoma.
In our study, we followed the criteria presented in those publications in terms of histopathological assessment of the tumors, mainly those now regarded as in situ adenocarcinomas. However, contrary to what has occurred in some of the series cited by the authors of the new proposal, we included all cases in which the stage was confirmed at T1N0M0. Our study includes 104 patients who met those specified criteria and in whom all the surgical resections, radiological, and pathological evaluations were performed in the same institution. Clearly, as expected in a cancer center, most of the patients were carefully monitored, mainly those patients in whom a previous diagnosis of malignancy had been established. Thus, among our patient population, 48 patients had a previous history of malignancy, while in 56 patients the pulmonary neoplasm was the only malignancy established. Univariable and multivariable statistical analyses looking at the clinical aspects, such as 36 20 o2 cm e Yoshizawa et al. 37 8 Not provided Sakurai et al. 38 25 0.5-3.0 cm Yim et al. 40 42 is, in our opinion, not a reliable predictor of such, as none of our patients had recurrent disease during the specified follow-up period. We did, however, note a trend towards better prognosis, although not statistically significant, in all those tumors with a lepidic component (P ¼ 0.058). However, when we further substratified this group by proportion of the lepidic component, we encountered no statistically significant difference between lepidic tumors and non-lepidic tumors. Furthermore, we encountered only six cases in which the radiological findings were of a pure ground-glass opacity that correlated with six cases of pure lepidic growth pattern on histology. That in itself also casts some doubt as to the validity of that particular feature to identify cases with a lepidic histological growth pattern, as 13 additional cases showed histological evidence of pure lepidic growth. It is important to underscore the fact that currently, among other parameters, we are using the pathology gross size of the specimen to determine whether to label these tumors as in situ adenocarcinoma and not the radiological measurement of the tumor. Using the radiological tumor size would make more sense if we were attempting to avoid more radical procedures. Our follow-up information in the 56 patients in whom there was no other history of malignancy showed that seven patients had died after a median followup of 57 months. It is likely that these patients did not die of recurrent or widespread disease, even though we were not able to determine the exact cause of death. On the basis of these results, we consider that the term in situ adenocarcinoma and minimally invasive adenocarcinoma are premature terms that may actually be misleading in the treatment of these patients. These terms should in no way deter surgeons from performing staging procedures in these patients, which brings us back to the use of the clinical significance of these terms. This fact is well illustrated by Takizawa et al, 43 who reported a study of 157 patients who underwent lobectomy and complete hilar/mediastinal lymphadenectomy for small peripheral adenocarcinomas between the sizes of 1.1 and 2.0 cm, and found that 17% of the patients had metastatic disease in lymph nodes. However, more interesting is the fact that 8% of these tumors were coded as well-differentiated adenocarcinomas. Similar findings were also encountered by Konaka et al, 44 who reported 171 patients, 136 of whom had peripheral adenocarcinomas with a tumor size o2.0 cm. The authors found 22% of patients with lymph node metastasis in tumors between 1.5 and 2.0 cm, whereas no tumor metastasis was present in tumors o1.0 cm. They concluded that systematic mediastinal and lymph node dissection is necessary even for patients with a tumor size o2.0 cm.
Our results clearly reveal no statistically significant difference between all these groups, mainly lepidic and non-lepidic T1N0M0 adenocarcinomas, thus diminishing the importance of terms such as in situ or minimally invasive adenocarcinoma. On the basis of our results, we consider that the outcome for patients with T1N0M0 disease is still best determined by proper staging rather than by changes in the pathology nomenclature of adenocarcinoma. We also consider that more studies should be conducted with actual series of cases instead of merely performing a literature review before any change in the nomenclature is seriously considered. In addition, the choice of surgical treatment for these patients, whether lobectomy or wedge resection, should be made based on clinical and radiological grounds rather than making such a choice based on histology alone by tissue biopsy.
Hence, we suggest the following approach for adenocarcinomas on biopsy or resected specimens:
On biopsy: J Adenocarcinoma with lepidic or bronchioloalveolar growth pattern (for tumors 40.5 cm).
